XTL Biopharmaceuticals Ltd.
XTLB | NASDAQ
$2.37
-$0.01 (-0.42%)
Sep 22, 2026, 12:35 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.14 | -3.38 | -0.13 | -1.21 | 8.66 | -1.33 |
PEG Ratio | 0 | 0.04 | 0 | 0 | -0.08 | -0.01 |
PS Ratio | n/a | 7.57 | n/a | n/a | n/a | n/a |
PB Ratio | -3.84 | 0.63 | 0.62 | 0.41 | 0.69 | 1.08 |
P/FCF Ratio | -0.95 | -2.04 | -1.95 | -1.83 | -3.51 | -4.58 |
P/OCF Ratio | -0.95 | -2.11 | -1.95 | -1.83 | -3.51 | -4.58 |
OCF/S Ratio | n/a | -358.76 | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | -1.06 | 0.03 | n/a | n/a | n/a | n/a |
Quick Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27 | 24.10 |
Current Ratio | 0.40 | 0.61 | 9.93 | 20.35 | 27 | 24.10 |
Asset Turnover | n/a | 0.05 | n/a | n/a | n/a | n/a |
Interest Coverage | -241.14 | -25.26 | -191.30 | -80.01 | -49.10 | -55.77 |
Return on Equity | 2.74K% | -18.90% | -0.08% | -33.71% | 8.16% | -21.65% |
Return on Assets | -4.2K% | -12.01% | -0.07% | -32.20% | 6.57% | -12.03% |
Return on Invested Capital | -11.25K% | -29.75% | -34.46% | -22.01% | -16.14% | -15.17% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | 0.67% | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | -227.72% | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | -256.54% | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | -481.60% | n/a | n/a | n/a | n/a |
FCF Margin | n/a | -370.73% | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | -206.21% | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove XTLB